Abstract: A simpler ADC production method is provided. A method for producing an antibody-drug conjugate including the following step: the step of conjugating a glycan-homogenized antibody and a glycosylated drug. The glycosylated drug consists of a drug bound to a glycan having an oxazolinated reducing end via a linker. The glycan-homogenized antibody and the glycosylated drug can be conjugated with an endo-P-N-acetylglucosaminidase mutant enzyme.

Abstract: A polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof achieves both an in vivo half-life extending effect of polyethylene glycol modification and the retainment of bioactivity. The polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof has one molecule of forked-type polyethylene glycol covalently bound to two molecules of the hepatocyte growth factor or the active fragment thereof at each of their respective carboxyl-terminal regions to form a homodimer.

Abstract: A method of inhibiting accumulation of body cavity fluid in a subject in need thereof includes administering a covalent conjugate of interferon with polyalkylene glycol to the subject wherein the polyalkylene glycol is polyethylene glycol, the interferon is type I interferon or interferon-?, and the type I interferon is interferon-? or interferon-?.

Abstract: An inhibitory agent for body cavity fluid accumulation exerts a drug efficacy on body cavity fluid accumulation that is resistant to administration of diuretics, and is capable of exerting therapeutic effects even by systemic administration. The inhibitory agent for body cavity fluid accumulation includes, as an active ingredient, a covalent conjugate of interferon with polyalkylene glycol.

Abstract: A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided.

Abstract: A method for producing an interferon-? complex includes binding interferon-? to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, sugar alcohols thereof, and C2-6 polyhydric alcohols.

Abstract: A method for producing an interferon-? complex includes binding interferon-? to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, sugar alcohols thereof, and C2-6 polyhydric alcohols.

Abstract: The present invention relates to a complex between interferon-? and polyethylene glycol, which has high biological activity, and to a method for producing the complex at high efficiency. Namely, the present invention relates to a method for producing an interferon-? complex comprising binding interferon-? to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, their corresponding sugar alcohols, and C2-6 polyhydric alcohols, and to an interferon-? complex produced by the method, which has polyethylene glycol specifically bound with lysine located at the 19th or 134th position in the amino acid sequence of interferon-?.

Abstract: A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided.

Abstract: An object of the present invention is to provide a therapeutic agent for allergy which realizes enhancement of therapeutic efficacy and improvement in side effects such as anaphylaxis in a method for treating allergy by allergen administration (hyposensitization therapy). That is, the present invention provides the therapeutic agent for allergy comprising a liposome having on its surface an oligosaccharide capable of binding to a lectin derived from an antigen presenting cell and composed of 2 to 11 sugar residues, wherein an allergen is encapsulated in said liposome.

Abstract: The present invention relates to a complex between interferon-? and polyethylene glycol, which has high biological activity, and to a method for producing the complex at high efficiency. Namely, the present invention relates to a method for producing an interferon-? complex comprising binding interferon-? to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, their corresponding sugar alcohols, and C2-6 polyhydric alcohols, and to an interferon-? complex produced by the method, which has polyethylene glycol specifically bound with lysine located at the 19th or 134th position in the amino acid sequence of interferon-?.